Induction of tyrosine kinase receptor b by retinoic acid allows brain-derived neurotrophic factor-induced amyloid precursor protein gene expression in human sh-sy5y neuroblastoma cells by Ruiz-León, Y. & Pascual, Ángel
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
UN
CO
RR
EC
TE
D 
PR
OO
F
INDUCTION OF TYROSINE KINASE RECEPTOR B BY RETINOIC ACID
ALLOWS BRAIN-DERIVED NEUROTROPHIC FACTOR-INDUCED
AMYLOID PRECURSOR PROTEIN GENE EXPRESSION IN HUMAN SH-
SY5Y NEUROBLASTOMA CELLS
Y. RUIZ-LEO´N AND A. PASCUAL*
Consejo Superior de Investigaciones, Instituto de Investigaciones Bio-
me´dicas Cientı´ficas, Arturo Duperier, 4, 28029 Madrid, Spain
Abstract—Retinoic acid (RA) is a potent regulator of morpho-
genesis, growth and cell differentiation. Incubation with RA
causes arrest of proliferation and neurite extension in SH-
SY5Y cells, a neuroblastoma cell line of human origin. In
these cells, RA regulates the expression of the -amyloid
precursor protein. The retinoid increases the levels of intra-
cellular and secreted forms of APP (amyloid precursor pro-
tein), APP–mRNA levels and the activity of the APP promoter
in transient transfection studies. These responses require
long periods of exposition to the ligand, thus suggesting a
nondirect effect of the RA receptors on the APP gene. Also in
these cells, RA induces the expression of TrkB, the tyrosine
kinase receptor for brain-derived neurotrophic factor (BDNF),
and 4 days of pretreatment with retinoic acid confers BDNF
responsiveness to the APP promoter. © 2003 Published by
Elsevier Science Ltd on behalf of IBRO.
Key words: -amyloid precursor protein, APP, promoter, neu-
roblastoma cells, retinoic acid, RA, brain-derived neurotro-
phic factor, BDNF, tyrosine kinase receptor, TrkB.
The -amyloid protein (A4), the major component of the
Alzheimer-associated plaques is derived from a set of
alternatively spliced -amyloid precursor proteins (APP)
which are encoded by a single gene located on human
chromosome 21 (for a review see Selkoe, 2001). Although
the biological function of this protein remains to be fully
elucidated, at physiological levels APP appears to be in-
volved in neurotrophic events and modulates functions
such as neuronal excitability, synaptic plasticity, neurite
outgrowth, synaptogenesis, or cell survival (for a review
see Mattson, 1997). In contrast, its overexpression may
contribute to increased production and deposit of A4, and
finally to activation of processes which cause cellular de-
generation (Calhoun et al., 1999; Yoshikawa et al., 1992).
APP is ubiquitously expressed in mammalian tissues and
its expression can be regulated by a variety of stimuli,
including ligands of the nuclear superfamily of steroid/
thyroid hormone receptors (Belandia et al., 1998; Konig et
al., 1990; Yoshikawa et al., 1990), and ligands of mem-
brane tyrosine kinase receptors (Ruiz-Leon and Pascual,
2001; Villa et al., 2001). The 5' promoter region of the APP
gene has been cloned and characterized for both humans
(Lahiri and Robakis, 1991; Salbaum et al., 1988) and
rodents (Hoffman and Chernak, 1994). The promoter lacks
a TATA or CAAT boxes, but contains other consensus
sequences for binding of a number of transcription factors.
However, the molecular mechanisms that control its ex-
pression are not well understood.
Induction of APP expression by retinoic acid (RA) has
been described in a number of cell lines of neuronal and
non neuronal origin (Beckman and Iverfeldt, 1997; Hung et
al., 1992; Lahiri and Nall, 1995). The effects of RA are
mediated by nuclear receptors (RARs), which normally
function as ligand-inducible transcription factors by binding
to response elements (RAREs) located in the regulatory
region of target genes. RARs are encoded by three differ-
ent genes which give rise to three different isoforms (, 
and ; Glass, 1994). As has been previously described,
neuroblastoma primary tumor tissue and cell lines express
RAR, and also RAR to a lesser degree. RAR is ex-
pressed at very low levels, but is strongly induced by
treatment with RA (Carpentier et al., 1997; Lovat et al.,
1993).
In SH-SY5Y cells, a clonal derivative of the human
neuroblastoma SK-N-SH cell line which expresses high
levels of RAR (Lovat et al., 1993), RA has been shown to
increase APP mRNA levels. In agreement with these re-
sults, we found that RA not only increased mRNA levels
but also the levels of intracellular and secreted APP pro-
tein. However, the effects of RA on APP gene expression
are delayed when compared with other effects induced by
this ligand on the same cells. In addition, a 48 h treatment
with RA was unable to stimulate APP promoter activity in
transient transfection assays. An increased activity of the
promoter was only observed following 4–6 days of incu-
bation in the presence of RA. These results again suggest
an indirect mechanism, likely mediated by other APP pro-
moter-interacting proteins.
Tyrosine kinase receptor B (TrkB) is the high-affinity
Trk for brain-derived neurotrophic factor (BDNF), a neuro-
trophin that is known to promote the structure and function
of the nervous system. TrkB mediates most of the BDNF-
induced responses and a synergistic effect of RA and
BDNF on neurite generation has been reported (Mey and
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Rombach, 1999). Moreover, RA stimulates TrkB expres-
sion in neuroblastoma cells (Encinas et al., 1999; Kaplan
et al., 1993; Kobayashi et al., 1994), and as we have
described, exogenous BDNF induces APP promoter activ-
ity in SH-SY5Y cells transiently transfected with an expres-
sion vector for TrkB (Ruiz-Leon and Pascual, 2001).
To probe a potential cross-talk between the response
induced on APP by RA and BDNF in SH-SY5Y cells, we
have analyzed the effects of RA on APP and TrkB expres-
sion in SH-SY5Y cells, and the effects of BDNF in
SH-SY5Y cells cultured in the presence or absence of RA.
EXPERIMENTAL PROCEDURES
Cell culture
SH-SY5Y cells were cultured in RPMI medium containing 10%
fetal bovine serum (Gibco Life Technologies Ltd., Paislay, Scot-
land, UK). The same medium was used to analyze the effect
induced by RA, but not the effects induced by BDNF on the APP
promoter activity, which were determined in experiments carried
out in RPMI medium supplemented with 0.5% serum. At the times
indicated in the text, media and cells were collected and pro-
cessed, or stored frozen for posterior analysis.
Chemicals
Polyclonal antibody 369A against the cytoplasmic domain of APP
was a generous gift of Dr. Samuel E. Gandy and the monoclonal
antibody 22C11, which recognizes the amino terminus of APP,
was purchased from Boehringer Mannheim (Germany). BDNF
and “all trans” RA were from PeproTech Ltd. (London, UK), and
Sigma-Aldrich (St. Louis, MO, USA). The anti-TrkB monoclonal
antibody was from Transduction Laboratories (Lexington, USA),
and the trk inhibitor K-252a from Calbiochem (Darmstadt,
Germany).
Reporter plasmids and expression vectors
The chloramphenicol acetyl transferase (CAT) reporter plasmid
containing the1099/105 fragment of the human APP gene has
been previously described (Belandia et al., 1998). The cDNA
encoding the TrkB receptor was inserted into the EcoRI site of the
expression vector CMV5, which contains the SV40 early pro-
moter. The R-140-Luc construct containing the fragment 124 to
14 of the human RAR2 promoter has been described previ-
ously by Vivanco-Ruiz et al. (1991).
DNA transfection
SH-SY5Y cells were transfected in Dulbecco’s Modified Eagle
medium (DMEM) containing 10% fetal calf serum. The 10% se-
rum-containing RPMI growing culture medium was replaced by
DMEM 4 to 6 hours before transfection, and the cells were co-
transfected by the calcium phosphate coprecipitation method with
5 g of the reporter plasmid (1099CAT, or R-140-Luc) and 5 g
of carrier DNA (high molecular mass calf thymus DNA). After 16 h
of incubation in the presence of calcium phosphate, the medium
was replaced with fresh RPMI, growing medium was added and
the cells incubated in the presence or in the absence of 1 M RA
for the time periods studied. In all cases, the total amount of DNA
among different transfections was kept constant by addition of an
empty noncoding expression vector. To analyze the effects of
BDNF, RA-pretreated cells were cotransfected with the reporter
plasmid 1099CAT and 2 g of a TrkB expression vector, and
transfection medium replaced with 0.5% serum-containing RPMI.
The cells were then cultured in the presence or in the absence of
10 g/ml BDNF. CAT activity was determined by incubation of
[14C]-chloramphenicol with cell lysate protein. After autoradiogra-
phy, the non-acetylated and acetylated [14C]-chloramphenicol was
quantified and the data expressed as the percentage of acetylated
forms after each treatment. Each experiment was repeated at
least two to three times with similar relative differences in regu-
lated expression.
RNA extraction and hybridization
Total RNA was extracted from SH-SY5Y cells, cultured in the
presence or in the absence of 1 M RA, with guanidinium thiocy-
anate (Chomczynski and Sacchi, 1987). The RNA (30 g) was
electrophoresed in 1% formaldehyde-agarose gels and trans-
ferred to nylon-nitrocellulose membranes for Northern blot analy-
sis. After staining with 0.02% Methylene Blue the blots were
hybridized, as described by Church and Gilbert (1984), with a
plasmid containing the human APP cDNA, or the rat TrkB cDNA,
labeled by random oligonucleotide priming. Hybridization was at
65 °C in PSE buffer (0.3 M sodium phosphate, pH 7.2, 7% SDS,
1 mM EDTA). The quantification of APP-mRNA levels shown in
Fig. 2 was carried out by densitometric scan of the autoradio-
grams, and corrected by the total amount of RNA applied.
Western blot analysis
Cellular proteins were extracted by lysis with a buffer (150 mM
NaCl, 50 mM Tris pH 8, 2 mM EDTA, 1% Triton X-100, 0.1% SDS)
containing the protease inhibitors PMSF (1 mM) and leupeptin
(10 g/ml). Equal amounts, 40 g, of cell extracts were electro-
phoresed in an 8% SDS-polyacrylamide gel, transferred to an
immobilon polyvinylidene difluoride membrane and the cellular
APP detected with the rabbit polyclonal antibody 369A. Secreted
full-length APP isoforms were detected by the same method from
50 l (1:100 from total) of conditioned medium using the mono-
clonal antibody 22C11 at a final concentration of 10 g/ml. To
determine TrkB, cellular proteins were extracted by lysis with a
modified RIPA buffer (20 mM MOPS, 150 mM NaCl, 1 mM EDTA,
1% NP-40, 1% NaDOC, 0.1% SDS), in the presence of protease
inhibitors, and the TrkB levels determined from 40 g aliquots with
a monoclonal antibody, which recognizes both the full-length 145
kDa, and the 95 kDa forms of TrkB.
Proliferation assays: [3H]thymidine incorporation
DNA synthesis rate was determined by measuring the incorpora-
tion of [3H]thymidine. Cells were plated in 96-well multiwells at an
initial density of 4000 cells/well. Twenty-four hours later the grow-
ing medium was replaced by RPMI (200 l) containing 10% serum
and the cells were maintained at 37 °C by an additional 4 day
period. [3H]Thymidine (0.1  Ci) was added to the cultures during
the last 6 h of incubation. The cells were then transferred to glass
fiber filters and processed in a cell harvester. The radioactivity
associated to filters was measured with a scintillation counter.
Statistical analysis
Results are expressed as meansS.D. The differences between
means were evaluated by a Student’s t-test and considered sig-
nificant at P	0.05.
RESULTS
RA induces differentiation and decreases the
proliferation of SH-SY5Y cells
RA plays a major role in neuronal cell differentiation, thus
inducing neuroblastoma cells to differentiate in vitro by
extending neurites; a positive relationship between the in
vitro neuronal differentiation and APP expression has been
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previously described (Konig et al., 1990; Hung et al., 1992;
Pan et al., 1993; Rossner et al., 1998; Yang et al., 1999).
As shown in Fig. 1, a 4 day treatment of SH-SY5Y cells
with 1 M RA, promoted morphologic differentiation (panel
A) and these results were not essentially different from
those reported by other authors who used 10-fold higher
doses of RA (Konig et al., 1990; Beckman and Iverfeldt,
1997). Interestingly, BDNF did not induce any morphologic
change on cells when added alone, and did not further
increase morphologic changes induced by RA when both
agents were added together. In addition, 1 M RA also
induced a strong reduction of the cellular proliferation as
determined by thymidine incorporation (panel B).
Induction of APP expression by RA in SH-SY5Y cells
RA treatment of SH-SY5Y cells increases APP–mRNA
levels, as well as the accumulation of intracellular and
secreted isoforms of APP. The mRNA levels were deter-
mined in SH-SY5Y cells, that were incubated for 2 to 6
days in the presence or the absence of 1 M RA. As
illustrated in panel A of Fig. 2, which shows the results
obtained in a representative Northern blot analysis of RNA,
as well as the quantization of APP mRNA levels obtained
in two independent experiments, no changes were ob-
served after 2 days of incubation. However, a small but
significant increase of APP–mRNA levels was observed
after 4–6 days of treatment with RA.
In parallel, the effects of RA on the cell-associated APP
and the full-length soluble derivatives of APP released into
the culture medium were analyzed by Western blot using
the polyclonal antibody 369A or the monoclonal antibody
22C11, respectively. Results are depicted in panel B of
Fig. 2. As occurred with the APP–mRNA levels, the pres-
ence of 1 M RA in the culture medium for 4 days induced
a significant increase of both the intracellular (left) and
secreted (right) APP species.
Based on previous descriptions (Buxbaum et al., 1990;
Weidemann et al., 1989), the immunoreactive bands de-
tected with the antibody 369A contain at least six protein
species corresponding to immature and mature isoforms of
APP. Incubation of SH-SY5Y cells with RA for 4 days did
not affect the pattern of isoforms but led to a generalized
increase of the intracellular APP content. In addition, RA
induced a generalized increase of the APP-derived iso-
forms released to the culture medium.
Effects of RA on APP promoter activity in transiently
transfected SH-SY5Y cells
A stimulatory effect of RA on the APP promoter activity has
been previously described in rat primary hippocampal neu-
rons (Yang et al., 1998), and also in transiently transfected
PC12 pheochromocytoma cells pretreated with the retinoid
for 4 days (Lahiri and Nall, 1995). To prove a similar effect
of RA on the APP promoter activity in neuroblastoma cells,
Fig. 1. Effect of retinoic acid on cell differentiation and proliferation. A. Microphotographs of cells cultured for 4 days with or without 1 M retinoic acid.
B shows the effect of retinoic acid on [3H]thymidine incorporation. Treated and untreated cells were transferred to glass fiber filters, processed in a
cell harvester, and the radioactivity associated to filters was measured with a scintillation counter. Data are the meanS.D. values. Significant
(P	0.001) reduction by RA compared with control group is indicated (***).
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we have transfected the cells with the 1099CAT reporter
plasmid, a construct which contains the 1099/105 frag-
ment of the human APP gene. As observed in the previous
figures, the induction of APP by RA in SH-SY5Y cells
requires at least 4 days, and this response appears to be
very slow when compared with other responses induced
by this ligand on these neuroblastoma cells. In agreement
with those findings, Fig. 3 shows that in transient transfec-
tion assays, a 48 h incubation with RA strongly induces the
activity of the RAR2 promoter, which contains a well-
Fig. 2. Induction of APP expression by RA in SH-SY5Y cells. A. Autoradiogram (left) of a representative northern blot analysis of RNA extracted from
cells incubated in the presence or the absence of 1 M retinoic acid for the indicated times. APP mRNA levels (right) were determined by densitometric
scan of autoradiograms and corrected by the amount of rRNA applied. Data are expressed as fold induction above the levels found in control cells,
and represent meanS.D. values of four determinations (duplicates from two separate assays). Significance at P	0.005 is indicated “*” compared
with basal control B. Western blot analysis of intracellular (left) and secreted (right) APP isoforms in SH-SY5Y cells incubated for 4 days in the
presence or the absence of 1 M retinoic acid.
Fig. 3. Regulation of APP promoter activity by RA in SH-SY5Y cells. CAT activity was determined in SH-SY5Y cells transfected with a reporter plasmid
containing the 1099 to 105 region of the APP promoter (left panel). The right panel shows the effects induced by retinoic acid on a control reporter
plasmid (R-140-Luc) containing the fragment 124 to 24 of the RAR2 promoter. CAT and luciferase activities were measured after a 48 h period
of incubation in the presence or in the absence of 1 M RA. Data are expressed as fold-induction over the values obtained in the corresponding
untreated cells and are the meanS.D. of four data points obtained in two separate experiments. Significant reduction by RA compared with control
groups are indicated P	0.05 (*); P	0.01 (**); P	0.001 (***).
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defined RARE (right panel), but is unable to induce APP
promoter activity at that time period. The retinoid was able
to induce APP promoter activity only after 4–6 days of
treatment (left panel). In addition, a computer-assisted
study indicates that the APP gene promoter region, does
not contain a consensus RARE, thus supporting an indirect
mechanism, likely mediated by the previous induction of
other protein/s, but not directly mediated by binding of RA
receptors to a RARE in the APP gene promoter.
BDNF induces APP promoter activity in
RA-pretreated cells
As we have previously described, BDNF stimulates the
APP gene promoter in TrkB expressing SH-SY5Y cells,
whereas it is unable to induce a response in control TrkB-
untransfected cells (Ruiz-Leon and Pascual, 2001). In ad-
dition, as has also been described, RA may regulate the
expression of TrkB in neuroblastoma cell lines (Lucarelli et
al., 1995), which have become dependent on BDNF for
survival (Feng et al., 2001). To test whether or not RA
treatment could induce TrkB and confer BDNF responsive-
ness to the APP, we first determined the levels of TrkB in
SH-SY5Y cells incubated for 4 days in the presence or in
the absence of 1 M RA. As shown in panel A of Fig. 4, RA
induces the expression of the TrkB gene, increasing both
the TrkB–mRNA (left) and TrkB protein (right) levels in
SH-SY5Y cells after 4 days of treatment.
In addition, we have also analyzed the effects of BDNF
on APP promoter activity in SH-SY5Y cells pretreated with
RA. In order to analyze whether or not the RA-induced
expression of TrkB is enough to confer BDNF responsive-
ness to the APP promoter, cells were incubated in the
presence or in the absence of 1 M RA for 4 days, and
then cotransfected with the 1099-CAT reporter plasmid
(which contains the fragment 1099 to 105 of the APP
gene) and a TrkB-expressing vector, or the corresponding
empty noncoding control vector. As shown at the left of
panel B, treatment of RA-untreated cells with 10 ng/ml
BDNF for 48 h leads to a significant increase of CAT
activity in TrkB expressing transfected cells, but is unable
Fig. 4. RA induces TrkB expression and confers APP promoter responsiveness to BDNF in SH-SY5Y cells. TrkB levels (messenger and cellular
protein) were analyzed after 4 days of incubation in the presence or the absence of 1 M RA. Panel A illustrates the mRNA (left) and cellular TrkB
(right) determined from 30 g of total RNA or 40 g of cellular protein, by Northern and Western blot analysis, respectively. In the Northern blot assays,
the 18 S rRNA from the stained blots were used as a control of the amounts of RNA applied. Panel B. After 4 days of treatment with or without 1 M
retinoic acid, cells were transiently transfected with an APP promoter-containing reporter plasmid (1099CAT), and with or without an expression vector
for TrkB, as indicated. CAT activity was determined after 48 h of incubation with BDNF. Data are expressed relative to the activity obtained in control
cells pretreated in the absence of retinoic acid and no treated with 10 ng/ml BDNF, and are the meanS.D. of CAT activities obtained from three
different experiments performed with duplicates. Significance, P	0.01 (**) or P	0.001 (***), is indicated. Panel C. Northern blot analysis (autoradio-
gram and densitometric scan) of RNA extracted from cells incubated with RA in the absence or in the presence of inhibitor K-252a. Similar results were
obtained in an additional experiment.
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to increase the basal activity in TrkB-untransfected cells,
which express very low levels of TrkB. In contrast, as
shown at the right side of the panel, CAT activity was
significantly induced by BDNF in cells preincubated for 4
days in the presence of 1 M RA, even in the absence of
transfected TrkB. Moreover, as illustrated in panel C of the
figure, the levels of APP–mRNA induced by RA were
markedly decreased in the presence of the trk inhibitor
K-252a (0,2 M). Altogether, these results suggest that
treatment of cells with RA which, as shown in panel A, is
able to induce TrkB expression, is sufficient to confer
BDNF responsiveness in APP promoter.
DISCUSSION
In the present work we have demonstrated that treatment
with RA can induce TrkB expression in SH-SY5Y cells, and
confer BDNF responsiveness to the APP gene promoter.
The effects of RA are mediated by RAR, which belong
to the subfamily of nonsteroid nuclear hormone receptors.
SH-SY5Y cells, a neuroblastoma cell line of human origin,
express RAR (Lovat et al., 1993), and the expression of a
number of genes has been described to be directly mod-
ulated by RA in these cells. Also in SH-SY5Y cells, 10 M
RA has been reported to activate APP expression, specif-
ically increasing the APP695–mRNA isoform, as proved by
S1 nuclease protection assay (Konig et al., 1990).
We have demonstrated that exposition to 1 M RA, a
smaller and more physiological dose, is able to induce the
expression of the APP gene increasing not only the total
APP mRNA levels, but also the intracellular and extracel-
lular content of APP. However, this response requires a
relatively long exposition to RA (4–6 days), and strongly
suggests a non-direct mediated mechanism. Although with
slight differences, these results are similar to those de-
scribed by Beckman and Iverfeldt (1997) in the same
cellular line. According to these authors, a higher dose of
RA (10 M) induces an increase of the APP messenger
levels, which appears to be significant only after 6 days of
treatment.
The delayed response of the APP gene could be ex-
plained by the presence of low levels of RA receptor.
Nevertheless, such a possibility appears to be diminished
since as shown in Fig. 3, the retinoid was unable to induce
APP promoter activity in transient transfection assays at a
time in which this compound is very effective in increasing
the activity of the R-140-Luc construct (Vivanco-Ruiz et al.,
1991) which contains the fragment 124 to 14 of the
human RAR2 promoter. In addition, a theoretical analysis
of the APP gene, reveals that the APP promoter does not
contains a consensus, or even an imperfect, RARE. These
results strongly suggest that activation of APP by RA is not
directly mediated by binding of RARs to sequences of the
APP promoter, and may require the previous activation of
other protein(s), which in turn could affect APP gene
expression.
In this respect, it has been reported that RA effectively
induces the expression of the BDNF receptor TrkB in
neurons (Kaplan et al., 1993). Both BDNF and TrkB, are
highly expressed in the adult hippocampus, one of the
most affected tissues in Alzheimer’s disease, and we have
previously described that BDNF induces APP expression
in SH-SY5Y cells transiently expressing TrkB (Ruiz-Leon
and Pascual, 2001). In addition, it has been suggested that
RA may induce BDNF responsiveness of sympathetic neu-
rons by alteration of Trk neurotrophin receptors expression
(Kobayashi et al., 1994). Therefore, the effects induced by
RA on the APP expression in SH-SY5Y cells could be
mediated by the previous increase of TrkB levels. Although
SH-SY5Y cells express very low amounts of TrkB receptor,
RA has been described to induce a sustained increase in
TrkB-mRNA that is already detectable at the second day of
treatment and leads to a significant elevation of TrkB levels
(Kaplan et al., 1993). In contrast, as has been also de-
scribed, SH-SY5Y cells express TrkB, and RA specifically
decreases TrkB-mRNA levels in the same cell line
(Ehrhard et al., 1993). Those discrepancies could be sec-
ondary to the experimental conditions maintained by both
groups, or even due to specific cellular properties associ-
ated to the cellular clones of SH-SY5Y used. In order to
validate our model we first analyzed the effects induced by
RA on TrkB expression in our cells. Although with minor
differences, our results are in agreement with those de-
scribed by Kaplan et al. (1993). We have found that 4 days
of treatment with 1 M RA significantly increases the levels
of both TrkB mRNA and protein, as determined by North-
ern and Western blot, respectively. Moreover, we have
also found that RA induces BDNF responsiveness of the
APP promoter, thus proving that RA-induced TrkB is func-
tionally active. Without RA treatment, APP promoter activ-
ity was very low and was minimally induced by BDNF. In
contrast, the neurotrophin led to a significant increase of
APP promoter activity in cells exposed to RA for 4 days. As
a control, in cells not exposed to RA, this response was
only found after transfection of TrkB. Finally, the effects
induced by RA on APP mRNA were substantially dimin-
ished in the presence of the Trk inhibitor K-252a, further
confirming a TrkB-mediated mechanism.
BDNF, a member of the neurotrophin family, protects
neurons against cellular insult (Cheng and Mattson, 1994),
and promotes survival in human neuroblastoma cells
(Middlemas et al., 1999). Furthermore, it has been sug-
gested that neurodegeneration may be, at least in part,
secondary to an alteration in BDNF and/or TrkB levels. In
agreement with this hypothesis, the use of BDNF as a
potential therapeutic agent in patients with Alzheimer’s
disease has been proposed (Ferrer et al., 1999; Mufson en
al., 1999). Our results suggest that RA may substantially
intensify the effects of BDNF by increasing the expression
of its receptor TrkB; this would open the possibility of using
both agents, RA and BDNF in a coordinate way. Unfortu-
nately, APP overexpression is also considered a risk factor
for Alzheimer’s disease. Therefore, both the beneficial ef-
fects induced by the neurotrophin on cellular survival, and
the negative and toxic effects that accompany APP over-
expression, should be considered. Moreover, although the
molecular events that regulate the expression of TrkB and
the effects induced by the BDNF/TrkB system in neurons
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are poorly understood, it results plausible that BDNF-in-
duced effects are controlled by RA, through a very sensi-
tive and accurate mechanism which determines the levels
of TrkB and hence the BDNF-induced effects. An exhaus-
tive analysis of the mechanisms involved in the responses
induced by RA on TrkB and APP would result of maximal
interest for the development of therapeutic strategies.
Our results suggest that RA may substantially intensify
the effects of BDNF by increasing the expression of its
receptor TrkB, and it results plausible that BDNF-induced
effects are controlled by RA, through a very sensitive and
accurate mechanism which determines the levels of TrkB
and hence the BDNF-induced effects. These results open
the possibility of using both agents, RA and BDNF, coor-
dinately, and this would be of maximal interest for the
development of therapeutic strategies. However, it is evi-
dent that new experiments should be carried out to eval-
uate the physiological relevance of these findings. First, an
important effort should be made to elucidate whether these
mechanisms are also observed in vivo, and definitely
prove that RA and BDNF functionally interact in neurons
and intact tissues.
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